{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-335192","form_type":"8-K","ticker":"INVA","cik":"0001080014","company_name":"Innoviva, Inc.","filed_at":"2026-08-05T20:19:21+00:00","discovered_at":"2026-08-05T20:20:02.250397+00:00","generated_at":"2026-08-05T20:20:17.489301+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Innoviva Q2 2026 revenue up 19% to $119.6M; net loss $83.4M on $161M fair-value charge","bullets":["Total revenue $119.6M (+19% YoY); net product sales $51.8M (+46% YoY) driven by IST growth.","Net loss $83.4M ($1.14 loss per share) due to $161M unfavorable fair-value change in equity investments (Armata).","Royalty revenue from GSK stable at $59.8M; IST U.S. net product sales $36.6M (+26% YoY).","Launched Nortiva Bio for long-acting oral drug delivery; XACDURO licensing deal with Dr. Reddy's for emerging markets.","Repurchased 1.4M shares for $31.4M in Q2; cash $570.4M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-335192","json":"https://secwatch.observer/filing/0001193125-26-335192.json","markdown":"https://secwatch.observer/filing/0001193125-26-335192.md","text":"https://secwatch.observer/filing/0001193125-26-335192.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1080014/000119312526335192/0001193125-26-335192-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1080014/000119312526335192/d228097d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T20:20:17.489301+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}